In conclusion, by dividing patients with BRAF-mutated metastatic melanoma into three prognostic categories based on the baseline assessment of ECOG PS, LDH, and metastatic sites, we noted a different activity and efficacy of both targeted therapies and AntiPD1 monotherapy. This evidence concerns the gene BRAF and metastatic melanoma.